NCT02666898已完成2 期
Phase II, Multicenter, Trial, Exploring "Chemo-free" Treatment (GA101+Ibrutinib) and MRD-driven Strategy in Previously Untreated Symptomatic B-chronic Lymphocytic Leukemia Medically Fit. A FILO Study. A Study From the Goelams/GCFLLC/MW Intergroup
French Innovative Leukemia Organisation1 个研究点 分布在 1 个国家目标入组 135 人开始时间: 2015年10月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 135
- 试验地点
- 1
- 主要终点
- Study treatment response
研究概览
简要总结
Phase II study testing chemo-free induction therapy with Ibrutinib + Obinutuzumab nine months /
Study Part 1:
All patients will receive 8 courses of GA101 + ibrutinib 420mg PO every 28 days
Study Part 2:
After evaluation at D1 of month 9:
If patients are in CR with BM MRD < 10-4, they will continue ibrutinib alone at a dose of 420mg daily If patients have BM MRD >10-4 whatever IWCLL 2008 responses or PR they will receive four courses of GA101 + FC at 28-day intervals + Ibrutinib PO until final evaluation of M16
详细描述
Phase II study testing chemo-free induction therapy with Ibrutinib + Obinutuzumab during nine months followed by a MRD-driven strategy. Assessment of response as well as bone marrow MRD evaluation will be performed at Day 1 month 9:
- Patients reaching CR with marrow MRD below 10-4 threshold will continue ibrutinib during 6 additional months.
- Patients in PR or bone marrow MRD > 10-4 will receive Ibrutinib during 6 additional months and 4 courses of FC+ GA101. At Day 1 Month 16, patients in CR but with MRD> 10-4 will continue Ibrutinib until progressive disease.
- Patients in stable or progressive disease will be excluded out of the trial.
Final evaluation of response (with BM MRD) will be performed at Day 1 Month 16.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient information and written informed consent
- •Age 18 years or older
- •Immunophenotypically confirmed B-CLL (IWCLL2008 and Matutes score 4 or 5)
- •Binet stage C according to IWCLL 2008 criteria or Binet stage A and B with active disease could be considered for inclusion.
- •Patients with no prior treatment (chemotherapy, radiotherapy, immunotherapy) except steroids for less than 1 month
- •Absence of 17p deletion as assessed by FISH (< 10 % positive nuclei)
- •Performance status ECOG < 2
- •CIRS (Cumulative Illness Rating Scale) ≤ 6 (see appendix 4 for calculation of CIRS score) Mandatory inclusion criteria for treatment with ibrutinib
- •Hematology values must be within the following limits:
- •Absolute neutrophil count (ANC) <1 G/L independent of growth factor support
- •Platelets <100 G/L or <50 G/L if bone marrow involvement independent of transfusion support in either situation
- •Biochemical values within the following limits:
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper limit of normal (ULN)
- •Total bilirubin ≤ 1.5 x ULN unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin
- •Serum creatinine ≤ 2 x ULN or estimated Glomerular Filtration Rate (Cockroft Gault≥ 40 mL/min/1.73m2
- •Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials. Men must agree to not donate sperm during and after the study. For females, these restrictions apply for 1 month after the last dose of study drug. For males, these restrictions apply for 3 months after the last dose of study drug.
- •Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [Beta-hCG]) or urine pregnancy test at Screening. Women who are pregnant or breastfeeding are ineligible for this study.
- •Sign (or their legally-acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study, including biomarkers, and are willing to participate in the study
排除标准
- •Binet stage A and B without active disease according to IWCLL 2008 criteria
- •Known HIV seropositivity
- •Hepatitis B or C seropositivity (unless clearly due to vaccination)
- •Active hemolysis (isolated positive DAT is not an exclusion criteria)
- •Life expectancy < 6 months
- •Patient refusal to perform the bone marrow biopsy for evaluation points
- •Clinically significant auto-immune anemia
- •Active second malignancy currently requiring treatment (except basal cell carcinoma in situ endometrial carcinoma and incidental prostate carcinoma) and/or less than 5 years CR after breast cancer
- •Any severe co-morbid conditions such as Class III or IV heart failure, myocardial infarction within months, unstable angina, ventricular tachyarrhythmias requiring ongoing treatment, severe chronic obstructive pulmonary disease with hypoxemia, uncontrolled diabetes mellitus, or uncontrolled hypertension
- •Concomitant disease requiring prolonged use of corticosteroids (> 1 month)
- •Known hypersensitivity with anaphylactic reaction to humanized monoclonal antibodies or any of the study drugs
- •Contraindication to the use of Obinutuzumab.
- •Contraindication to use of Ibrutinib
- •Transformation to aggressive B-cell malignancy (e.g. diffuse large cell lymphoma, Hodgkin lymphoma, or prolymphocytic leukaemia)
- •Active bacterial, viral or fungal infection
- •Abnormal renal function with creatinine clearance < 60 ml/min calculated according to the formula of Cockcroft and Gault
- •Total bilirubin, gamma glutamyltransferase or transaminase levels > 2.5 ULN.
- •Any coexisting medical or psychological condition that would preclude participation in the required study procedures
- •Patient with mental deficiency preventing proper understanding of the requirements of treatment.
- •Pregnant or breastfeeding women.
- •Adult under law-control
- •Fertile male and female patients who cannot or do not wish to use an effective method of contraception, during and for 18 months after the final treatment used for the purposes of the study.
- •No affiliate to social security
- •Mandatory exclusion criteria for treatment with Ibrutinib
- •Major surgery within 4 weeks of randomization.
- •Known central nervous system lymphoma.
- •History of stroke or intracranial hemorrhage within 6 months prior to randomization.
- •Requires anticoagulation with warfarin or equivalent vitamin K antagonists
- •Requires treatment with strong CYP3A inhibitors.
- •Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification.
- •Vaccinated with live, attenuated vaccines within 4 weeks of randomization.
- •Known history of human immunodeficiency virus (HIV) or active Hepatitis C Virus or active Hepatitis B Virus infection or any uncontrolled active systemic infection requiring intravenous (IV) antibiotics.
- •Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk.
研究组 & 干预措施
Obinutuzumab and Ibrutinib CLL treatment
Experimental
3 parts
PART 1: 6 cycles of GA101 + Ibrutinib 420mg PO/ 28 days:
GA101:
C 1 D1: 100mg, D2: 900mg D8 and D15: 1000 mg i.v C 2 to 6 :D1 1000 mg i.v
Ibrutinib:
D3 Month 1 to Day 30 Month 15: 420mg daily PO
PART 2: 4 cycles / 28 days
After evaluation at D1 month 9:
- patients in CR with BM MRD < 10-4, Ibrutinib 420mg daily
- patients with BM MRD >10-4 or PR 4 courses of GA101 + FC/ 28-day + Ibrutinib PO until M16 Cycle 1 to 4 - GA101: 1000 mg i.v on day 1
- Fludarabine : 40 mg/m² per os, days 2-4, / 28 days
- Cyclophosphamide : 250 mg/m² per os, days 2-4, / 28 days
- Ibrutinib 420mg/day PO
PART 3 (only in GAI-FC+Ibru arm) :
After evaluation at D1 of M16:
- patients CR with BM MRD< 10-4, treatment stopped
- patients CR with BM MRD >10-4, Ibrutinib continued until PD or PB MRD becomes negative.
干预措施: GA101 (Drug)
Obinutuzumab and Ibrutinib CLL treatment
Experimental
3 parts
PART 1: 6 cycles of GA101 + Ibrutinib 420mg PO/ 28 days:
GA101:
C 1 D1: 100mg, D2: 900mg D8 and D15: 1000 mg i.v C 2 to 6 :D1 1000 mg i.v
Ibrutinib:
D3 Month 1 to Day 30 Month 15: 420mg daily PO
PART 2: 4 cycles / 28 days
After evaluation at D1 month 9:
- patients in CR with BM MRD < 10-4, Ibrutinib 420mg daily
- patients with BM MRD >10-4 or PR 4 courses of GA101 + FC/ 28-day + Ibrutinib PO until M16 Cycle 1 to 4 - GA101: 1000 mg i.v on day 1
- Fludarabine : 40 mg/m² per os, days 2-4, / 28 days
- Cyclophosphamide : 250 mg/m² per os, days 2-4, / 28 days
- Ibrutinib 420mg/day PO
PART 3 (only in GAI-FC+Ibru arm) :
After evaluation at D1 of M16:
- patients CR with BM MRD< 10-4, treatment stopped
- patients CR with BM MRD >10-4, Ibrutinib continued until PD or PB MRD becomes negative.
干预措施: Ibrutinib (Drug)
Obinutuzumab and Ibrutinib CLL treatment
Experimental
3 parts
PART 1: 6 cycles of GA101 + Ibrutinib 420mg PO/ 28 days:
GA101:
C 1 D1: 100mg, D2: 900mg D8 and D15: 1000 mg i.v C 2 to 6 :D1 1000 mg i.v
Ibrutinib:
D3 Month 1 to Day 30 Month 15: 420mg daily PO
PART 2: 4 cycles / 28 days
After evaluation at D1 month 9:
- patients in CR with BM MRD < 10-4, Ibrutinib 420mg daily
- patients with BM MRD >10-4 or PR 4 courses of GA101 + FC/ 28-day + Ibrutinib PO until M16 Cycle 1 to 4 - GA101: 1000 mg i.v on day 1
- Fludarabine : 40 mg/m² per os, days 2-4, / 28 days
- Cyclophosphamide : 250 mg/m² per os, days 2-4, / 28 days
- Ibrutinib 420mg/day PO
PART 3 (only in GAI-FC+Ibru arm) :
After evaluation at D1 of M16:
- patients CR with BM MRD< 10-4, treatment stopped
- patients CR with BM MRD >10-4, Ibrutinib continued until PD or PB MRD becomes negative.
干预措施: Cyclophosphamide (Drug)
Obinutuzumab and Ibrutinib CLL treatment
Experimental
3 parts
PART 1: 6 cycles of GA101 + Ibrutinib 420mg PO/ 28 days:
GA101:
C 1 D1: 100mg, D2: 900mg D8 and D15: 1000 mg i.v C 2 to 6 :D1 1000 mg i.v
Ibrutinib:
D3 Month 1 to Day 30 Month 15: 420mg daily PO
PART 2: 4 cycles / 28 days
After evaluation at D1 month 9:
- patients in CR with BM MRD < 10-4, Ibrutinib 420mg daily
- patients with BM MRD >10-4 or PR 4 courses of GA101 + FC/ 28-day + Ibrutinib PO until M16 Cycle 1 to 4 - GA101: 1000 mg i.v on day 1
- Fludarabine : 40 mg/m² per os, days 2-4, / 28 days
- Cyclophosphamide : 250 mg/m² per os, days 2-4, / 28 days
- Ibrutinib 420mg/day PO
PART 3 (only in GAI-FC+Ibru arm) :
After evaluation at D1 of M16:
- patients CR with BM MRD< 10-4, treatment stopped
- patients CR with BM MRD >10-4, Ibrutinib continued until PD or PB MRD becomes negative.
干预措施: Fludarabine (Drug)
结局指标
主要结局
Study treatment response
时间窗: month 16
MRD
次要结局
- progression free survival(month 16)
- overall survival(month 16)
- time to next treatment(36 months)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's LymphomasNon-Hodgkin's LymphomaAnn Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueAnn Arbor Stage II Follicular LymphomaAnn Arbor Stage II Nodal Marginal Zone LymphomaAnn Abor Stage III B-Cell Non-Hodgkin LymphomaAnn Arbor Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueAnn Arbor Stage III Follicular LymphomaAnn Arbor Stage III Nodal Marginal Zone LymphomaAnn Arbor Stage IV B-Cell Non-Hodgkin LymphomaAnn Arbor Stage IV Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueAnn Arbor Stage IV Follicular LymphomaAnn Arbor Stage IV Nodal Marginal Zone LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular LymphomaIndolent Non-hodgkin LymphomaStage II Splenic Marginal Zone LymphomaStage III Splenic Marginal Zone LymphomaStage IV Splenic Marginal Zone LymphomaNCT03198026Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University29
终止
2 期
Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCCHead and Neck CancerSquamous Cell Carcinoma of the Head and NeckNCT03646461University of California, San Diego5
招募中
2 期
Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLLChronic Lymphocytic LeukemiaNCT04908228Paolo Ghia53
已完成
2 期
Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLLLeukemia, Lymphocytic, ChronicNCT02758665University of Ulm41
进行中（未招募）
1 期
Study to compare the efficacy and safety of the combinaison of venetoclax+ibrutinib in patients with untreated mantle cell lymphomantreated mantle cell lymphomaMedDRA version: 20.0Level: PTClassification code 10061275Term: Mantle cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004910-37-BEYSARC194